Sirna And Drug Delivery

We have collected information about Sirna And Drug Delivery for you. Follow the links to find out details on Sirna And Drug Delivery.


Delivery systems for siRNA drug development in cancer ...

    https://www.sciencedirect.com/science/article/pii/S1818087614000646
    The attitude of big pharmaceutical companies to RNAi drugs has also become over-optimistic. In summary, a good delivery system is the key to siRNA drug development. Once research into siRNA drug delivery systems makes a significant breakthrough, siRNA will occupy a strong position in the drug market, especially the anti-cancer drug market.Author: Cong-fei Xu, Jun Wang

The current state and future directions of RNAi-based ...

    https://www.nature.com/articles/s41573-019-0017-4
    Mar 07, 2019 · The RNA interference (RNAi) pathway regulates mRNA stability and translation in nearly all human cells. Small double-stranded RNA molecules can …Author: Ryan L. Setten, Ryan L. Setten, John J. Rossi, John J. Rossi, Si-ping Han, Si-ping Han

Advances in the delivery of RNA ... - Genome Medicine

    https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0450-0
    Jun 27, 2017 · Delivery materials. Broadly speaking, RNA delivery can be mediated by viral and non-viral vectors. For viral RNA delivery, there has been a great deal of interest in engineering adeno-associated viruses to carry nucleic acid cargo []—however, this section will focus mainly on the development of non-viral materials (Table 1).Of the non-viral RNA delivery vehicles, nanoparticles are perhaps ...Author: James C. Kaczmarek, Piotr S. Kowalski, Daniel G. Anderson

Delivery of siRNA Therapeutics: Barriers and Carriers

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
    Jun 11, 2010 · The site of action of siRNA therapeutics is the cytosol. The barriers to siRNA delivery are multiple and depend on the targeted organs and the administration routes. In general, locoregional delivery of siRNA has fewer barriers compared to systemic delivery.Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au

Drug Delivery of siRNA Therapeutics

    https://www.mdpi.com/1999-4923/12/2/178/pdf
    This Special Issue of Pharmaceutics titled “Drug Delivery of siRNA Therapeutics” aims to present the state of the art of siRNA delivery, embracing investigation strategies of international research groups with di erent experiences and skills. The Special Issue will thus be devoted to presentingAuthor: Gaetano Lamberti, Anna Angela Barba

Drug delivery of siRNA therapeutics: potentials and limits ...

    https://www.sciencedirect.com/science/article/pii/S1549963408000828
    Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. ... Current CPP-mediated siRNA delivery approaches can be divided in two main categories: noncovalent CPP-siRNA in complex by virtue of electrostatic interactions, and CPPs covalently attached to siRNA duplexes through disulfide bond formations. ... Many studies on ...Author: Daniela Reischl, Andreas Zimmer

Dendrimers for siRNA Delivery

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816686/
    The flow cytometry data representing the efficiency of the polymer for siRNA-drug co-delivery are also shown. This study clearly demonstrated that lipid modification enhances the cellular association of the nanocarrier without compromising the siRNA condensation ability of the dendrimers.Author: Swati Biswas, Vladimir P. Torchilin

Pharmaceutics Special Issue : Drug Delivery of siRNA ...

    https://www.mdpi.com/journal/pharmaceutics/special_issues/drug_delivery_of_siRNA_therapeutics
    After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery. Full article

FDA Approves First-Ever siRNA Therapy Biologics Blog

    https://www.biologicsblog.com/fda-approves-first-ever-sirna-therapy/
    Aug 10, 2018 · Today FDA approved the first-ever “small interfering RNA” (siRNA) product, marking a significant milestone in the story of RNA interference (RNAi) technology and clearing the way for a new type of therapeutic. Alnylam® secured approval and Orphan Drug Designation for its siRNA product Onpattro (patisiran), a therapy for the rare hereditary disease transthyretin-mediated amyloidosis in ...

Approval of first RNA interference drug – why the excitement?

    https://phys.org/news/2018-08-rna-drug.html
    Aug 17, 2018 · The Food and Drug Administration recently approved the very first therapeutic small interfering RNA (siRNA), ... To improve the delivery of the drug to …Author: Thomas Schmittgen

Searching for Sirna And Drug Delivery?

You can just click the links above. The data is collected for you.

Related Delivery Info